| Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life. | |
| | |
MedLine Citation:
|
PMID: 20560803 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The goal of the present study was to evaluate the diagnostic accuracy of B-type natriuretic hormone (BNP) assay in children with congenital heart disease (CHD) in the first month of life. METHODS: BNP was measured in 152 neonates with CHD; 154 healthy children matched for age were used as controls. BNP was measured with a fully automated platform (Triage BNP reagents, Access Immunoassay Systems, Beckman Coulter, Inc., Fullerton, CA, USA). RESULTS: BNP values were significantly higher (p<0.0001) in newborns and infants with CHD compared with control (CHD patients: median 1167.5 ng/L, range 25-54,447 ng/L; healthy children: median 150.5 ng/L, range 5-866 ng/L). The diagnostic accuracy of BNP was assessed using the receiver operating characteristic (ROC) analysis, taking into account the three different groups divided according to age. Group 1: all CHD patients and healthy newborns and infants as a whole (i.e., from birth to the 30th day of life); Group 2: from the 1st to 3rd day of life; Group 3: from the 4th to 30th day of life. The area under the curve (AUC) of the ROC curve for Group 3 (0.935) was significantly higher than that for Group 1 (0.843, p=0.009) and Group 2 (0.769, p=0.0003), while the AUC values of Group 1 and Group 2 were not significantly different (p=0.191). CONCLUSIONS: BNP may be considered a useful marker for screening in the integrated approach of newborns, infants and children with suspected CHD. However, the accuracy of the BNP assay varies greatly during the first month of extra-uterine life, showing the lowest diagnostic accuracy in the first 3 days after birth. After the second week of life, the biomarker becomes more accurate in ruling in CHD. |
| | |
Authors:
|
Massimiliano Cantinotti; Simona Storti; Andrea Ripoli; Luc Zyw; Maura Crocetti; Nadia Assanta; Bruno Murzi; Aldo Clerico |
Related Documents
:
|
11875603 - Maternal deaths due to pre-existing cardiac disease. 12923863 - Vasomotor instability in neonates with chromosome 22q11 deletion syndrome. 22648333 - A preterm infant with benign neonatal hemangiomatosis and persistent patent ductus arte... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical chemistry and laboratory medicine : CCLM / FESCC Volume: 48 ISSN: 1434-6621 ISO Abbreviation: Clin. Chem. Lab. Med. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-22 Completed Date: 2011-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9806306 Medline TA: Clin Chem Lab Med Country: Germany |
Other Details:
|
Languages: eng Pagination: 1333-8 Citation Subset: IM |
Affiliation:
|
Fondazione Toscana G. Monasterio, G. Pasquinucci Hospital, Pisa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Case-Control Studies Female Heart Diseases / blood*, diagnosis*, genetics Humans Infant, Newborn Male Natriuretic Agents / blood* ROC Curve Sensitivity and Specificity Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Natriuretic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tamsulosin as an expulsive therapy for steinstrasse after extracorporeal shock wave lithotripsy: a r...
Next Document: Improving quality of life in hemodialysis: impact of an occupational therapy program.